Atrial Fibrillation Flashcards
Components of CHA2DS2VASc Score
C: Congestive HF
H: HTN
A: Age > 75 years (2 pts)
D: Diabetes
S: Stroke/TIA/Systemic Embolism (2 pts)
V: Vascular Disease
A: 65-74 years
Sc: Female
Anticoagulation indicated in men with a CHA2DS2VASc Score ≥ ___
2
Anticoagulation indicated in women with a CHA2DS2VASc Score ≥ ___
3
HASBLED Componenets
H: HTN - SBP > 160 mm Hg
A: Abnormal liver/kidney function (1 each)
S: Stroke history
B: Bleeding history
L: Labile INR
E: Elderly > 65 years
D: Drug/Alcohol abuse (1 each)
Lenient Rate Control HR Goal
110 bpm
Patients who qualify for Lenient Rate Control
Asymptomatic AND EF > 40%
Strict Rate Control HR Goal
< 80 bpm
Patients who qualify for Strict Rate Control
Symptomatic OR EF ≤ 40%
Type of Cardioversion in Hemodynamically Unstable Patient
Immediate DCCV
Type of Cardioversion in Symptomatic Patient Desite Rate Control
DCCV, Chemical Cardioversion, or Both
Type of Cardioversion in a Patient Unable to Achieve Rate Control
DCCV, Chemical Cardioversion, or Both
Type of Cardioversion in a Patient Unable to Achieve Rate Control
DCCV, Chemical Cardioversion, or Both
Vaughan-Williams Class I Anti-arrhythmic Class
Sodium Channel Blockade
Vaughan-Williams Class I Anti-arrhythmics
Ia: Disopyramide, quinidine, procainamide
1b: Lidoacine, mexiletine
1c: Flecainide, Propafenone
Vaughan-Williams Class II Anti-arrhythmics Class
Beta-blockers
Vaughan-Williams Class III Anti-arrhythmics Class
Potassium Channel Blockade
Vaughan-Williams Class III Anti-arrhythmics
Sotalol, dofetilide, amiodarone, dronedarone, ibutilide
Vaughan-Williams Class IV Anti-arrhythmic Class
CCB
Antiarrhythmics that can be used for ACUTE chemical cardioversion
Flecainide, propafenone, dofetilide, amiodarone, ibutilide
Antiarrhythmics that can be used for CHRONIC Rhythm Control
Flecainide, propafenone, sotalol, dofetilide, amiodarone, dronedarone
Class IC Antiarrythmics Metabolism/DDI
CYP2D6
Propafenone specific AE
Metallic Taste
Dofetilide Initation
3 days inpatient
Dofetilide DDI
Verapamil: decreases absorption
HCTZ: Impacts clearance/electrolytes
Metformin/Trimethoprim: Competes for active tubular secretion
Additive QT prolongation
Dofetide CI Renal Funciton
< 20 mL/min
Sotalol Initiaton
3-days inpatient
Sotalol DDI
Additive QT prolongation
Sotalol CI Renal Function
< 40 mL/min
Amiodarone Half-Life
~50 days
Amiodarone DDI
Inhibits: CYP3A4, 2D6, 2C9, PGP
Additive QT prolongation
Amiodarone load goal
8-10 grams over 2-4 weeks
Amiodarone AEs
- Bradycardia
- QT prolongation
- Pulmonary fibrosis
- Thyroid dysfunction (hypo or hyper)
- Corneal deposits
- Hepatotoxicity
- Blue/Gray Skin
Amiodarone Monitoring
- Baseline ECG, Q3-6 months
- Baseline TFTs, Q6 months
- Baseline LFTs, Q6 months
- Baseline CXR, Q12 months
- Baseline PFTs, Q12 months
Dronedarone Brand
Multaq
Dronedarone CI
HF, permanent AF
Dronedarone metabolism/DDI
Inhibits: CYP3A4, 2D6, PGP
Additive QT prolongation
Dronedarone AE
- Bradycardia
- QT prolongation
- Hepatotoxicity